shr-a1912
mAbexperimentalADC
Clinical trial activity
19 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
15
Phase 3
3
Phase 4
0
Earliest trial started Dec 6, 2021 (NCT05113069)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Neoadjuvant Therapy · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 3
- Salivary Gland Neoplasms · Phase 2
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
- Payload
- Unclear
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06929624 | Phase 3 | Apr 24, 2025 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06649331 | Phase 2 | Oct 21, 2024 | Fudan University |
| NCT06470672 | Phase 2 | Jul 31, 2024 | Fudan University |
| NCT06480136 | Phase 2 | Jul 15, 2024 | Huazhong University of Science and Technology |
| NCT06385678 | Phase 1/Phase 2 (Phase 2) | Jul 5, 2024 | Hengrui Therapeutics, Inc. |
| NCT06433609 | Phase 2 | Jun 30, 2024 | Government of China |
| NCT06465238 | Phase 2 | Jun 30, 2024 | Henan Medical University |
| NCT06434103 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06474455 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2024 | Hengrui Therapeutics, Inc. |
| NCT06394492 | Phase 3 | May 10, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06211023 | Phase 2/Phase 3 (Phase 3) | Feb 15, 2024 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT06210438 | Phase 2 | Feb 1, 2024 | Fudan University |
| NCT06145308 | Phase 2 | Dec 1, 2023 | Peking University |
| NCT06104553 | Phase 1/Phase 2 (Phase 2) | Nov 17, 2023 | Hengrui Therapeutics, Inc. |
| NCT05924256 | Phase 2 | Jul 26, 2023 | Fudan University |
| NCT05765032 | Phase 1/Phase 2 (Phase 2) | Dec 30, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05594875 | Phase 1 | Dec 1, 2022 | Atridia Pty Ltd. |
| NCT05154604 | Phase 1 | Dec 31, 2021 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| NCT05113069 | Phase 1 | Dec 6, 2021 | Hengrui Therapeutics, Inc. |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Suzhou Suncadia Biopharmaceuticals Co., Ltd. | For profit | 6 | 6 | 3 | 2021 |
| Fudan University | Academic/Hospital | 4 | 4 | 1 | 2023 |
| Hengrui Therapeutics, Inc. | For profit | 4 | 4 | 2 | 2021 |
| Atridia Pty Ltd. | For profit | 1 | 1 | 1 | 2022 |
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Henan Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2023 |
8 organizations
Page 1 / 1